Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction FOLFOX +/- Aflibercept in High Risk Rectal Cancer (RIA)
NCT02340949Phase 2Completed
- Sponsor
- GEMCAD
- Start
- Jan 2015
- Primary completion
- Jul 2019
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of aflibercept in rectal cancer, sponsored by GEMCAD. Started Jan 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02340949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02340949.